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The Ad Hoc Task Force of the Patient Reported
Outcomes Harmonization Group had an important
opportunity to interact with the FDA and move
toward consensus on unresolved issues within the
ﬁeld. The Task Force is to be commended for build-
ing bridges to the FDA and working for several
years to increase the level of regulatory acceptance
of outcomes research. No doubt these insights will
be incorporated in the forthcoming FDA guidance
on patient-reported outcomes. However, the initial
report of the Task Force, published in this issue of
Value in Health [1], has failed to communicate the
value of these meetings. The report does not men-
tion the areas of controversy and debate that led to
the need for meeting with the FDA, and deliberately
avoids providing prescriptions or recommenda-
tions, fearing they would inhibit the growth of the
ﬁeld.
Whereas it is entirely appropriate for the Task
Force to limit the relevance of their comments to the
drug approval and regulatory process, I disagree
that a set of prescriptions would limit our ﬁeld. In
fact, standards for the assessment of subjective var-
iables already exist, based on literally decades of
research by clinical and educational psychologists
[2]. The difﬁculty of applying these guidelines to
the drug development process should not obviate
the need for doing so. There are many places
where the Task Force could have further developed
a given issue, for example, the issue of patient verses
proxy reports. Patient and proxy can provide a dif-
ferent perspective, and in some instances, there is no
choice but to use proxies, i.e., when cognitive devel-
opment or impairment prevents the reporting of
valid self-referential opinions. As the Task Force
rightly points out, the proxy is more biased the less
observable the behavior or characteristic of the
patient—so at what point do we stop collecting the
proxy reports, or how do we interpret them? Can
we use proxies to identify drug beneﬁts? The report
raises these issues but does not provide any recom-
mendations. The issue of multidimensionality is
another issue the Task Force could have provided
more guidance on. While it is true that the requisite
number of domains to cover the concept of health-
related quality of life will vary from one disease to
another, would it not have been possible to make
a simple recommendation about minimal coverage
required?
Although there are many active debates going on
within the ﬁeld of outcomes research, to which the
Task Force alludes, they seem to have deliberately
avoided these debates and shied away from making
any statements that might help resolve the ques-
tions. For example, what is the consensus about
what constitutes sufﬁcient evidence for validation of
a new scale? Validation is an ongoing process, but at
what point can we agree that sufﬁcient evidence has
accumulated that would justify using a particular
scale for a regulatory submission? In diseases where
there are multiple scales available to measure out-
comes, how does a researcher select the most appro-
priate measure and avoid bias? How much needs to
be known about a scale before it can be used to
guide treatment? What would the authors recom-
mend around clinical trial designs which incorpo-
rate patient-reported outcomes? Should power
calculations be universally provided for such end-
points, so that results can be interpreted in the
context of the power of the instrument to detect
changes or treatment effects? What is the group’s
opinion about the use of item banks and computer-
ized adaptive testing during clinical trials for prod-
uct registration? Has the technology progressed to
the point where it can be considered comparable or
better than standard instruments? Should the FDA
and other regulators accept results based on such
technology? While it may not be possible yet to
endorse a speciﬁc model of health-related quality of
life above all others, which models were consid-
ered?  Certainly, there are excellent models available
that illustrate the integration of subjective and clin-
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ical outcomes [3,4]. A discussion of clinical signiﬁ-
cance, and commentary on the enormous problem
of missing data, is totally lacking. Should data on
responders only analyses be used to evaluate the
effects of drugs? The authors provide examples of
these sorts of results without discussing the bias
potentially inherent in such analyses. Guidance
from this Task Force on these issues would have
been very helpful.
The distinction between “clinical” and “patient
reported” outcomes is unfortunate and contributes
to the conceptual lack of clarity that has plagued
outcomes research. Certainly this cannot be blamed
on the Task Force. The danger lies in confusing a
specialized methodology with the concepts it is used
to measure. However, the Task Force has not made
any recommendations about improving this situa-
tion, and instead has made statements such as to
collect patient-reported outcomes when “the treat-
ment arms offer equal clinical efﬁcacy but differen-
tial PRO beneﬁts.” What this statement means is
that patients might perceive differences between
treatments that would otherwise be undetectable.
This is a much more precise statement. The recom-
mendation that outcomes endpoints should be
treated by the same standards as clinical endpoints
is essential, though hardly original.
Whereas operational deﬁnitions and measure-
ment are cornerstones of the ﬁeld, the main purpose
of our research should be to demonstrate relation-
ships among constructs, evaluate treatment effects,
improve the health of samples or populations of
patients, and allow us to make predictions. We seem
to be lost in the forest of deﬁnition and measure-
ment, and need to do more to show the clinical ben-
eﬁts of incorporating the patients’ perspective. The
moniker “patient-reported outcomes” is unfortu-
nate even though it has helped improve the accept-
ance of the ﬁeld by FDA, primarily because it is
inaccurate (it also includes outcomes provided by
clinicians and proxy respondents), and also, one
might argue, because it contains no information
about the content of the ﬁeld. If no theoretical con-
tent should be alluded to in our label (i.e., we
moved away from describing our ﬁeld as “quality-
of-life measurement” because of the endless discus-
sions about deﬁnitions), perhaps a term such as
“perceived clinical outcomes” would be preferable
as more accurate, because it implies that the vari-
able being measured is perceived by a person,
whether a clinician, patient, or proxy. The Task
Force laments the lack of a “clearly developed con-
ceptual framework for understanding the relation-
ship between HRQL and PROs,” but this makes no
sense, as the term “patient-reported outcomes” has
no theoretical content.
In summary, the Task Force is to be commended
for their efforts to improve communication with
regulatory authorities and to harmonize recommen-
dations for measuring these outcomes across a vari-
ety of organizations. Unfortunately, little evidence
of this important work is apparent in the current
report, which holds way too much to safe territory
and provides little guidance on many important
issues facing the ﬁeld. While the issues raised in this
editorial are beyond the scope of any one paper to
answer, let’s hope the forthcoming papers from the
Task Force tackle at least some of them.
These statements reﬂect the personal opinions of the
author and should in no way be construed as representing
the opinion of Pﬁzer Inc.
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